Key result
Cutaneous eNOS or MnSOD gene therapy restores wound healing in diabetic mice by suppressing superoxide.
Why the study?
Nitric oxide deficiency contributes to impaired wound healing in type 1 diabetes, and the role of increased cutaneous superoxide levels in this process was investigated.
Does cutaneous gene therapy of eNOS or MnSOD restore delayed wound healing in type 1 diabetic mice?
Population
Streptozotocin-induced type 1 diabetic mice, Ins2 Akita diabetic mice, and normal control mice
Comparison
Cutaneous gene therapy of eNOS or MnSOD versus untreated diabetic mice and normal controls
Design
Preclinical experimental study with gene therapy interventions
Authors
Loading...
Hypothesis-generating in diabetic mice; leaves open whether cutaneous eNOS or MnSOD gene therapy improves human wound healing.
Does cutaneous gene therapy of eNOS or MnSOD restore delayed wound healing in type 1 diabetic mice?
Hyperglycemia-induced superoxide production via NADPH oxidase and PKC pathways impairs wound healing in type 1 diabetes, which can be restored by eNOS or MnSOD gene therapy.
Luo et al. (2004) studied Type 1 diabetes with delayed wound healing. Cutaneous gene therapy of eNOS or manganese superoxide dismutase (MnSOD) vs. Normal controls / untreated diabetic mice was evaluated on Wound healing delay and cutaneous superoxide levels. Cutaneous gene therapy with eNOS or MnSOD restored delayed wound healing in type 1 diabetic mice by suppressing wound superoxide levels and augmenting eNOS protein and activity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: